Nicoletta Colombo
#128,829
Most Influential Person Now
Researcher
Nicoletta Colombo's AcademicInfluence.com Rankings
Nicoletta Colomboengineering Degrees
Engineering
#4332
World Rank
#5522
Historical Rank
Cybernetics
#62
World Rank
#68
Historical Rank
Biomedical Engineering
#265
World Rank
#272
Historical Rank
Applied Physics
#1029
World Rank
#1054
Historical Rank
Download Badge
Engineering
Why Is Nicoletta Colombo Influential?
(Suggest an Edit or Addition)Nicoletta Colombo's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (2018) (1465)
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. (2017) (1151)
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (2017) (1039)
- ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. (2015) (888)
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. (2019) (829)
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (773)
- Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial (2003) (767)
- Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. (2009) (656)
- European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. (1994) (648)
- The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. (1995) (618)
- Ovarian cancer: screening, treatment, and followup. (1995) (579)
- ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma (2020) (559)
- Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) (515)
- Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial (2002) (514)
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. (2015) (478)
- Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. (2003) (466)
- Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (417)
- International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma. (2003) (411)
- ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. (2019) (385)
- ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer (2015) (351)
- Incorporation of pazopanib in maintenance therapy of ovarian cancer. (2014) (304)
- Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (293)
- Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2011) (283)
- Management of ovarian stromal cell tumors. (2007) (265)
- International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. (2003) (254)
- Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. (2019) (241)
- Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer (2010) (234)
- The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy‐induced peripheral neurotoxicity: comparison with the National Cancer Institute‐Common Toxicity Scale (2007) (218)
- Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (208)
- ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. (2019) (207)
- Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. (2021) (200)
- Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. (2005) (196)
- Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. (2016) (190)
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (190)
- Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale (2003) (171)
- Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. (2005) (166)
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019) (163)
- Sentinel node biopsy in early vulvar cancer (2000) (159)
- Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. (2022) (157)
- ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. (2015) (151)
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study. (2019) (150)
- Pelvic exenteration: ten-year experience at the European Institute of Oncology in Milan. (2009) (149)
- Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. (2002) (146)
- Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update (2015) (145)
- Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial (2010) (142)
- The forefront of ovarian cancer therapy: update on PARP inhibitors. (2020) (139)
- Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial (2020) (136)
- Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. (2013) (136)
- Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (129)
- Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary. (1986) (126)
- Robotic approach for cervical cancer: comparison with laparotomy: a case control study. (2009) (122)
- Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study. (2013) (119)
- Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (118)
- Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. (2014) (111)
- VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study (2007) (111)
- Safety and dose modification for patients receiving niraparib (2018) (111)
- Controversial issues in the management of early epithelial ovarian cancer: conservative surgery and role of adjuvant therapy. (1994) (111)
- Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39) (2021) (109)
- Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. (2012) (108)
- Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial (2013) (107)
- Cisplatin‐lnduced peripheral neurotoxicity is dependent on total‐dose intensity and single‐dose intensity (1992) (106)
- Epigenome-based cancer risk prediction: rationale, opportunities and challenges (2018) (104)
- Pure Ovarian Immature Teratoma, a Unique and Curable Disease: 10 Years' Experience of 32 Prospectively Treated Patients (1994) (97)
- Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology About the Conservative Management of Ovarian Malignant Tumors (2011) (93)
- The Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.The Effect of Debulking Surgery After Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer (1996) (91)
- Surgical Management of Malignant Ovarian Germ‐Cell Tumors: 10 Years' Experience of 129 Patients (1995) (89)
- First-Line Therapy in Ovarian Cancer Trials (2011) (88)
- Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. (2010) (86)
- Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup (2014) (86)
- The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. (2008) (86)
- A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. (2012) (84)
- Anti‐tumor and immunomodulatory activity of intraperitoneal IFN‐γ in ovarian carcinoma patients with minimal residual tumor after chemotherapy (1992) (83)
- CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells (2018) (83)
- Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. (2021) (82)
- Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months (2018) (81)
- Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. (1990) (81)
- Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues. (2016) (81)
- Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16). (2013) (80)
- Survival with Cemiplimab in Recurrent Cervical Cancer. (2022) (80)
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (80)
- A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. (2013) (79)
- Chemo-conization in early cervical cancer. (2007) (78)
- Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. (2007) (78)
- Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)). (1990) (76)
- Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer. (2001) (74)
- The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling (2011) (73)
- Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (72)
- Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. (2019) (72)
- Early Oral Versus “Traditional” Postoperative Feeding in Gynecologic Oncology Patients Undergoing Intestinal Resection: a Randomized Controlled Trial (2009) (70)
- Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Sex Cord Stromal Tumors (2014) (70)
- Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression (2013) (69)
- Erratum: The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial (Lancet (2003) 361 (2099-106)) (2003) (67)
- Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy (1989) (67)
- Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer. (2018) (65)
- ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. (2015) (64)
- Optimal treatment of early-stage ovarian cancer (2014) (63)
- Reduction of Postoperative Complication Rate with the Use of Early Oral Feeding in Gynecologic Oncologic Patients Undergoing a Major Surgery: A Randomized Controlled Trial (2009) (63)
- Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study. (2012) (61)
- Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (59)
- Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. (2018) (58)
- Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval (2010) (57)
- Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status. (2019) (57)
- Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice. (1998) (56)
- Tumor‐derived chemotactic factor(S) from human ovarian carcinoma: Evidence for a role in the regulation of macrophage content of neoplastic tissues (1985) (56)
- Role of conservative surgery in ovarian cancer: the European experience (2005) (56)
- Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients. (2015) (56)
- Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study. (2018) (55)
- Intraperitoneal administration of interferon β in ovarian cancer patients (1985) (55)
- Results from a phase 1/2 study of volociximab in combination with liposomal doxorubicin in relapsed advanced epithelial ovarian and primary peritoneal carcinoma (2008) (55)
- Robotic surgery: changing the surgical approach for endometrial cancer in a referral cancer center. (2009) (53)
- Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin. (2014) (53)
- Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. (2020) (52)
- Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. (2016) (52)
- Special issues in fertility preservation for gynecologic malignancies. (2016) (51)
- Intravenous aflibercept in patients with platinum‐resistant, advanced ovarian cancer: Results of a randomized, double‐blind, phase 2, parallel‐arm study (2014) (51)
- The role of restaging borderline ovarian tumors: single institution experience and review of the literature. (2010) (51)
- Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. (2021) (51)
- Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday. (2018) (51)
- TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33 / AGO‐OVAR OP7). (2017) (51)
- International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. (2003) (51)
- Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study (2017) (50)
- Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). (2016) (50)
- Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. (2021) (50)
- Weekly cisplatin ± glutathione in relapsed ovarian carcinoma (1994) (50)
- External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma (2013) (50)
- Peripheral neurotoxicity of taxol in patients previously treated with cisplatin (1995) (47)
- FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. (2018) (47)
- MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum (2020) (46)
- Defective natural killer activity within human ovarian tumors: low numbers of morphologically defined effectors present in situ. (1983) (46)
- BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. (2016) (46)
- Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. (2019) (46)
- Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. (2021) (46)
- Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells’ vulnerability to DNA-damaging agents (2017) (45)
- Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships. (2009) (45)
- Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial (2020) (45)
- Detection of Sentinel Nodes by Lymphoscintigraphy and Gamma Probe Guided Surgery in Vulvar Neoplasia (2000) (44)
- Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. (2019) (44)
- ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma (2021) (43)
- Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial. (2019) (43)
- Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. (2020) (43)
- Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. (2019) (43)
- Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum‐free interval: Myth or reality? (2017) (42)
- 811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1 (2020) (42)
- Development of a lipid-rich, soft plaque in rabbits, monitored by histology and intravascular ultrasound. (2000) (41)
- Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin? (2004) (41)
- Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer (2016) (40)
- SENTINEL NODE DETECTION IN CERVICAL CANCER (2003) (40)
- Neoadjuvant chemotherapy in cervical cancer: an update (2015) (39)
- Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study. (2018) (39)
- Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer (2016) (39)
- Effects of granulocyte‐monocyte colony‐stimulating factor (GM‐CSF) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancer‐associated macrophages (1995) (39)
- Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial. (2015) (38)
- Corrections to "Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2018) (38)
- Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis. (2017) (37)
- WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia (2011) (37)
- Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors. (2010) (37)
- Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective. (2017) (36)
- Corrections to "Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2018) (36)
- Diffusion-weighted MR imaging in assessing cervical tumour response to nonsurgical therapy (2011) (36)
- Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. (2022) (36)
- Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future (2017) (36)
- Non-epithelial ovarian cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2009) (35)
- The Systemic Treatment of Recurrent Ovarian Cancer revisited. (2021) (35)
- Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation. (2016) (35)
- Transplacental passage of cyclophosphamide. (1982) (34)
- Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients. (2014) (34)
- Are monoclonal antibodies a safe treatment for cancer during pregnancy? (2013) (33)
- Low-dose oral etoposide in epithelial cancer of the ovary. (1993) (33)
- Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial (2022) (33)
- Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer. (2011) (33)
- Building clinical trials around patients: Evaluation and comparison of decentralized and conventional site models in patients with low back pain (2018) (33)
- Phase II clinical study of BBR 3464, a novel, bifunctional platinum analogue, in patients with advanced ovarian cancer (2001) (31)
- The disposition of carboplatin in ovarian cancer patients (2004) (31)
- Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours. (2016) (31)
- Uterine serous carcinoma. (2021) (31)
- Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. (2017) (31)
- A Phase I-II Preoperative Biomarker Trial of Fenretinide in Ascitic Ovarian Cancer (2006) (31)
- FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC) (2019) (31)
- Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia. (2013) (30)
- LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial (2021) (30)
- Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells. (1983) (30)
- Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors. (2014) (30)
- Imaging in gynecological disease (8): ultrasound characteristics of recurrent borderline ovarian tumors (2013) (30)
- Follow-up in Gynecological Malignancies: A State of Art (2015) (29)
- Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer (2019) (29)
- A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. (2020) (29)
- Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. (2021) (27)
- What have we learned from ICON1 and ACTION? (2003) (27)
- ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. (2021) (27)
- Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: Preliminary results of a pilot study (2008) (26)
- Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial. (2015) (26)
- Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia (2017) (25)
- Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. (2021) (25)
- Diaphragmatic Surgery During Primary Cytoreduction for Advanced Ovarian Cancer: Peritoneal Stripping Versus Diaphragmatic Resection (2011) (25)
- Platinum-Based Neoadjuvant Chemotherapy Followed by Radical Surgery for Cervical Carcinoma International Federation of Gynecology and Obstetrics Stage IB2-IIB (2013) (24)
- Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy (2019) (24)
- Pre-operative evaluation of epithelial ovarian cancer patients: Role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery. A single-centre study. (2019) (24)
- Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer. (1994) (24)
- Adult granulosa cell tumours of the ovary (2014) (24)
- The Work Place Educational Climate in Gynecological Oncology Fellowships Across Europe: The Impact of Accreditation (2015) (23)
- Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. (2018) (23)
- Diagnosis of persistent ovarian carcinoma with three-step immunoscintigraphy (2000) (23)
- Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90). (2013) (23)
- Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives. (2016) (23)
- Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit. (2017) (23)
- Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study. (2012) (23)
- Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial. (2019) (22)
- Characterization of small combinatorial chemistry libraries by (1)H NMR. Quantitation with a convenient and novel internal standard. (2001) (22)
- Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. (2016) (22)
- Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer. (2020) (22)
- Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer (2021) (22)
- An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens (2012) (22)
- The need for accredited training in gynaecological oncology: a report from the European Network of Young Gynaecological Oncologists (ENYGO). (2013) (22)
- Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study (2018) (21)
- A Large, Multicenter, Retrospective Study on Efficacy and Safety Of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. (2019) (21)
- In vitro and in vivo effects of cisplatin on the generation of lymphokine-activated killer cells. (1990) (21)
- Aggressive angiomyxoma of the vulva. (2004) (21)
- A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). (2013) (21)
- DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients. (2019) (20)
- Treatment Options for Pregnant Women With Ovarian Tumors (2014) (20)
- Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma (2019) (20)
- BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC) (2019) (20)
- LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line (2020) (20)
- Fertility-Sparing Options in Young Women with Cervical Cancer (2016) (20)
- Feasibility of Transabdominal Cardiophrenic Lymphnode Dissection in Advanced Ovarian Cancer: Initial Experience at a Tertiary Center (2017) (19)
- PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. (2016) (19)
- Concordance between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. (2020) (19)
- Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer. (2020) (18)
- Role of chemotherapy in relapsed ovarian cancer. (1999) (18)
- Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines. (2021) (18)
- Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2′-deoxyuridine (2004) (18)
- Appendix 5: Endometrial cancer: eUpdate published online 8 June 2017 (www.esmo.org/Guidelines/Gynaecological-Cancers). (2017) (18)
- Optimizing treatment of the partially platinum-sensitive ovarian cancer patient. (2013) (17)
- Trabectedin (T) in relapsed advanced ovarian cancer (ROC): A pooled analysis of three phase II studies (2007) (17)
- High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk‐oriented consolidation: A critical review of a 10‐year, single‐center experience in younger, non M3 AML patients (2016) (17)
- Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells (2007) (16)
- Splenectomy as Part of Primary Cytoreductive Surgery for Advanced Ovarian Cancer: A Retrospective Cohort Study (2012) (16)
- Efficacy of Trabectedin in Platinum-Sensitive-Relapsed Ovarian Cancer: New Data From the Randomized OVA-301 Study (2011) (16)
- European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Industry Partners—First Update 2015 (2015) (16)
- Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient (2014) (16)
- 1,3,4-Oxadiazole formation as traceless release in solid phase organic synthesis (2006) (16)
- Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). (2021) (16)
- Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study (2014) (15)
- ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies (2020) (15)
- Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. (2022) (15)
- Ultrasonographic diagnosis and longitudinal follow-up of recurrences after conservative surgery for borderline ovarian tumors. (2016) (15)
- Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials (2013) (15)
- Critical Review of Neoadjuvant Chemotherapy Followed by Surgery for Locally Advanced Cervical Cancer (2010) (15)
- Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial. (2018) (15)
- Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma (2015) (15)
- 726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775) (2021) (14)
- Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders. (2015) (14)
- Cisplatin (P), vinblastine (V), and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa cell tumor of the ovary (GCTO): An eortc gynecology cancer cooperative group study (1989) (14)
- Goserelin with chemotherapy to preserve ovarian function in premenopausal women with early breast cancer : menstruation and pregnancy outcomes (2012) (14)
- Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer. (2003) (14)
- Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future. (2017) (14)
- Intraperitoneal administration of interferon beta in ovarian cancer patients. (1985) (14)
- A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer (2021) (14)
- The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples (2022) (14)
- Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study (2021) (13)
- Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results. (1991) (13)
- A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma (2018) (13)
- Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. (2013) (13)
- Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series. (2017) (13)
- A blastic plasmacytoid dendritic cell neoplasm‐like phenotype identifies a subgroup of npm1‐mutated acute myeloid leukemia patients with worse prognosis (2018) (13)
- A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib. (2010) (13)
- Medical treatment of early stage and rare histological variants of epithelial ovarian cancer (2015) (13)
- Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes. (2015) (13)
- LBA40_PRARIEL3: A phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC) (2017) (13)
- Human ovarian tumors in primary culture: Growth, characterization and initial evaluation of the response to cis platinum treatment in vitro (1988) (13)
- Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis (2019) (13)
- Antibody-dependent and -independent cytotoxicity of human mononuclear phagocytes: defective stimulation of tumoricidal activity in milk macrophages. (1982) (13)
- Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information (2019) (12)
- Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary. (2020) (12)
- Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial (2021) (12)
- Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1 (2021) (12)
- Medical therapy of advanced malignant epithelial tumours of the ovary. (2000) (12)
- Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: single institution experience. (2012) (12)
- Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia). (2020) (12)
- The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC). (2017) (11)
- Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study. (2022) (11)
- Paclitaxel and cisplatin in ovarian cancer. (2000) (11)
- Platinum, Anthracycline, and Alkylating Agent-Based Chemotherapy for Ovarian Carcinosarcoma (2009) (11)
- ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer. (2020) (11)
- Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer. (1982) (10)
- Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial. (2022) (10)
- Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression (2012) (10)
- Single cell-derived spheroids capture the self-renewing subpopulations of metastatic ovarian cancer (2018) (10)
- ESGO Statement on the Role of CA‐125 Measurement in Follow-Up of Epithelial Ovarian Cancer (2012) (10)
- L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1/SRC/STAT3 signaling (2021) (10)
- Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD‐driven salvage approach (2019) (10)
- Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial. (2017) (10)
- Optimization of Diarylthiazole B‐Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated hERG Inhibition, and Low Paradoxical Effect (2015) (10)
- Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients (2004) (10)
- Final overall survival results from SOLO3: Phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1 - and/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer (026) (2022) (10)
- The interplay between NCAM and FGFR signalling underlies ovarian cancer progression (2011) (9)
- Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden (2020) (9)
- Robotic Versus Open Radical Hysterectomy in Women With Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy: A Single-institution Experience of Surgical and Oncologic Outcomes. (2016) (9)
- Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer (2022) (9)
- The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma (2020) (9)
- Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies (2022) (9)
- An active chemotherapy regimen for advanced ovarian sex cord-stromal tumors. (1999) (9)
- Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift? (2021) (9)
- Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for Stage IB2-IIB cervical cancer: EORTC55994 (2019) (9)
- Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: results of a multicenter retrospective Italian study. (2005) (9)
- Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer (2019) (9)
- Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge (2016) (9)
- Training in Bowel and Upper Abdominal Surgery in Gynaecological Oncology: European Society of Gynecological Oncology (ESGO) Statement (2011) (9)
- A phase II study of oral gimatecan (ST1481) in women with progressing or recurring advanced epithelial ovarian, fallopian tube and peritoneal cancers. (2006) (9)
- Fibroblastic Malignant Peripheral Nerve Sheath Tumour of the Uterine Cervix: Report of a Case and Literature Review With Emphasis on Possible Differential Diagnosis. (2018) (9)
- KEYNOTE-826: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. (2019) (9)
- 15th Biennial Meeting of the International Gynecologic Cancer Society (2014) (9)
- Tumor progression and metastatic dissemination in ovarian cancer after dose‐dense or conventional paclitaxel and cisplatin plus bevacizumab (2018) (8)
- Rosia: A Single-Arm Study in More Than 1000 Patients (PTS) Receiving Front-Line Bevacizumab (BEV) + Chemotherapy (CT) for Ovarian Cancer (OC) (2012) (8)
- Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC). (2014) (8)
- A Long‐Term Extension Study of Bevacizumab in Patients With Solid Tumors (2021) (8)
- Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. (2019) (8)
- AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. (2019) (8)
- AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results. (2018) (8)
- Overexpression of p185 is not related to erbB2 amplification in ovarian cancer. (1993) (8)
- Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial (2021) (8)
- A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis (2008) (8)
- ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma (2021) (7)
- Haemopoietic growth factors in myelodysplastic syndromes: towards patient-oriented therapy? (2005) (7)
- Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer (2019) (7)
- Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) (2021) (7)
- Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC). (2021) (7)
- ESGO statement on cervical cancer vaccination: August 2007 (2007) (7)
- When nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. (2017) (7)
- Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. (2021) (7)
- Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study (2020) (7)
- Intensity modulated radiation therapy boost in locally-advanced cervical cancer in the absence of brachytherapy (2020) (7)
- Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial (2019) (7)
- Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial. (2019) (7)
- Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis. (2020) (7)
- Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma. (2022) (7)
- Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. (2018) (7)
- 987TiPOReO/ENGOT Ov-38: A phase IIIb trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer (2017) (7)
- In search of specific cytotoxic T lymphocytes infiltrating or accompanying human ovarian carcinoma (2005) (6)
- Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer. (1996) (6)
- Molecular Recognition of T:G Mismatched Base Pairs in DNA as Studied by Electrospray Ionization Mass Spectrometry (2008) (6)
- The Role of Surgery in Gestational Trophoblastic Disease (1983) (6)
- In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay (2022) (6)
- Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study (2021) (6)
- Regioselective γ-Alkylation of tert-Butyl 2,4-Dioxopiperidine-1-carboxylate (2007) (6)
- Adult primary cervical rhabdomyosarcomas: A Multicentric cross-national case series (2019) (6)
- Feasibility of robotic radical hysterectomy after neoadjuvant chemotherapy in women with locally advanced cervical cancer. (2016) (6)
- CT-Based Radiomics and Deep Learning for BRCA Mutation and Progression-Free Survival Prediction in Ovarian Cancer Using a Multicentric Dataset (2022) (6)
- Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4. (2021) (6)
- Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. (2020) (6)
- PLATINUM COMBINATION CHEMOTHERAPY VERSUS PLATINUM MONOTHERAPY IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER: A META-ANALYSIS OF RANDOMISED TRIALS USING INDIVIDUAL PATIENT DATA (IPD) (2012) (6)
- A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer (2018) (6)
- Avelumab (MSB0010718C; anti-PD-L1) ± pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer: The phase III JAVELIN Ovarian 200 trial. (2016) (6)
- NATURAL KILLER ACTIVITY IN HUMAN OVARIAN TUMORS (1982) (6)
- Intervention debulking surgery (IDS) does increase survival in advanced epithelial ovarian cancer (OC); an EORTC gynecological cancer cooperative group (GCCG) study (1993) (6)
- Preliminary results from CECILIA, an open-label global safety study of bevacizumab (BEV), carboplatin (C) and paclitaxel (P) therapy for metastatic, recurrent or persistent cervical cancer (CC). (2018) (6)
- Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers. (2020) (6)
- Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6) (2022) (6)
- 392 Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III solo1 study (2020) (6)
- Clinical presentation, diagnosis and management of therapy‐related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly‐ADP‐ribose polymerase inhibitors: A single‐center experience (2020) (6)
- appendix 7: Ovarian cancer: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Gynaecological-Malignancies). (2016) (6)
- Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study. (2020) (6)
- Phase II study of the platinum analog TNO-6 in patients with advanced ovarian cancer. (1986) (5)
- Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study (LBA 4) (2022) (5)
- Pre‐transplant minimal residual disease assessment and transplant‐related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation (2021) (5)
- Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. (2020) (5)
- 33 Olaparib monotherapy versus (VS) chemotherapy for germline BRCA-mutated (GBRCAM) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (PTS): phase III solo3 trial (2019) (5)
- Safety and efficacy of extended bevacizumab (BEV) therapy in elderly (≥70 years) patients (pts) treated for newly diagnosed ovarian cancer (OC) in the international ROSiA study. (2016) (5)
- BEATcc (ENGOT-Cx10/GEICO 68-C/GOG3030/JGOG1084): A randomized, open label, phase III study of cisplatin and paclitaxel chemotherapy with bevacizumab (CTx plus B) with or without atezolizumab (Atz) as first-line treatment for metastatic, persistent, or recurrent (m/r) carcinoma of the cervix (CCx). (2019) (5)
- Alpha-fetoprotein in the management of germ cell tumors of the ovary. (1989) (5)
- 00099 THE SURVIVAL BENEFIT OF INTERVAL DEBULKING SURGERY (IDS) IN ADVANCED OVARIAN CANCER IS MAINTAINED DURING TEN YEARS; THE EORTC GCG 55865 STUDY (2005) (5)
- KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer (2019) (5)
- BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer. (2018) (5)
- DR antigen expression on ovarian carcinoma cells does not correlate with their capacity to elicit an autologous proliferative response (2004) (5)
- Outcome according to residual disease (surgeon's report vs pre‐chemotherapy imaging) in patients with bevacizumab‐treated ovarian cancer: Analysis of the ROSiA study (2019) (5)
- Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors (2022) (5)
- Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study. (2022) (5)
- Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. (2018) (5)
- Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: A randomized clinical trial (2004) (5)
- Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). (2020) (5)
- Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician’s choice (TPC). (2021) (5)
- Multimodality therapy of early-stage (FIGO I-II) ovarian cancer: review of surgical management and postoperative adjuvant treatment (1996) (5)
- Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial (2016) (5)
- 2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (2022) (5)
- Catumaxomab with and without prednisolone in patients with malignant ascites due to epithelial cancer: Results from the phase IIIb CASIMAS study. (2012) (4)
- Safety and dose modification for patients receiving niraparib. (2019) (4)
- AGO-OVAR 28/ENGOT-ov57: Niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer—A multicenter, randomized, phase III trial. (2022) (4)
- Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock (2022) (4)
- 327 Randomised trial of paclitaxel in combination with platinum chemotherapy versus platinum-based chemotherapy in the treatment of relapsed ovarian cancer (ICON4/OVAR 2.2) (2003) (4)
- A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer (2022) (4)
- High‐dose epirubicin in patients with advanced or recurrent uterine sarcoma (1997) (4)
- 1Rucaparib versus chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: efficacy and safety from ARIEL4, a randomized phase III study (2021) (4)
- Abstract LB-A12: Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive high-grade ovarian carcinoma (2018) (4)
- A phase II combination study of bortezomib with pegylated-liposomal doxorubicin in patients with ovarian cancer failing platinum containing regimens (2008) (4)
- Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial (2023) (4)
- Role of inhibin B in detecting recurrence of granulosa cell tumors of the ovary in postmenopausal patients (2021) (4)
- Synchronous and Metachronous Breast and Ovarian Cancer: Experience From Two Large Cancer Center (2020) (4)
- Lack of activity of cyclophosphamide in ovarian cancer patients refractory to cis-dichlorodiammine platinum (2004) (4)
- Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes (2022) (4)
- Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial. (2019) (4)
- High precision radiotherapy including intensity-modulated radiation therapy and pulsed-dose-rate brachytherapy for cervical cancer: a retrospective monoinstitutional study (2019) (4)
- Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab (BEV), carboplatin (C) and paclitaxel (P) for advanced cervical cancer (aCC) (2019) (4)
- Feasibility and safety of front-line bevacizumab (BEV)-containing therapy after neoadjuvant (NA) chemotherapy (CT) for ovarian cancer (OC): The ROSiA experience. (2013) (4)
- Teniposide in refractory ovarian cancer: a phase II study. (1984) (4)
- Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3 (2021) (4)
- How to Address Sexual Problems in Female Cancer Patients. (2017) (4)
- III.4 Tamoxifen and the Uterus: Potential Uterine Risks of Anti-oestrogens. The Approach of the European Institute of Oncology (1998) (4)
- Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia (2006) (3)
- KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma. (2022) (3)
- Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment (2020) (3)
- De novo AML patients with favourable–intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened “GO question” (2013) (3)
- Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study (2023) (3)
- A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer. (2022) (3)
- Exploratory analysis of percentage of genomic loss of heterozygosity (LOH) in patients with platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3. (2018) (3)
- Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study. (2018) (3)
- Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial. (2015) (3)
- A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer (2020) (3)
- Randomized phase II study of sapanisertib (SAP) + paclitaxel (PAC) versus PAC alone in patients (pts) with advanced, recurrent, or persistent endometrial cancer. (2020) (3)
- O003/#557 Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (2022) (3)
- BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories (2019) (3)
- Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and updated safety data from the phase 3 study ARIEL3. (2019) (3)
- Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. (2019) (3)
- ACTION + ICON1: two parallel randomised phased III trials comparing adjuvant chemotherapy to no adjuvant chemotherapy following surgery in women with high risk early ovarian cancer (2001) (3)
- First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research (2020) (3)
- Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial. (2017) (3)
- 932PDEfficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21) (2017) (3)
- Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE‐826 (2022) (3)
- Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety (2021) (3)
- Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers (2020) (3)
- Cervical re-injection of indocyanine green to improve sentinel lymph node detection in endometrial cancer. (2021) (3)
- Post hoc exploratory analysis of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma from the randomized, placebo-controlled phase III study ARIEL3: Effect of a deleterious germline or no germline mutation on efficacy (2019) (3)
- Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS) (2019) (3)
- Randomized, phase Ib/II study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer (2019) (3)
- A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia. (2019) (3)
- 8004 ORAL Safety and Efficacy Outcomes in Heavily and Non-heavily Pretreated Patients With Recurrent Ovarian Cancer (ROC) After Single-agent Trabectedin Treatment – Pooled Analysis of Phase II Trials (2011) (3)
- Abstract 734: Thienoindoles: New highly promising agents for antibody-drug conjugates generation (2018) (2)
- Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients (2022) (2)
- Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of the ACTO study (2021) (2)
- AFTER TEN YEARS FOLLOW-UP INTERVAL DEBULKING SURGERY REMAINS A SIGNIFICANT PROGNOSTIC FACTOR FOR SURVIVAL AND PROGRESSION FREE SURVIVAL FOR ADVANCED OVARIAN CANCER: THE EORTC GYNAECOLOGICAL CANCER GROUP STUDY (2004) (2)
- Endometrial carcinosarcoma (2022) (2)
- Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase III study ARIEL3 of rucaparib maintenance treatment (2019) (2)
- 2022-RA-873-ESGO Validation study of the ‘NOGGO-GIS ASSAY’ based on ovarian cancer samples from the first-line PAOLA-1/ENGOT-ov25 phase-III trial (2022) (2)
- Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab (2022) (2)
- Tolerability of long-term use of trabectedin (Tr) in combination with pegylated liposomal doxorubicin (PLD) in patients (pts) with relapsed ovarian cancer (ROC). (2010) (2)
- Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa. (2009) (2)
- 186 Surgical outcome as prognostic factor in different histologic subtypes of ovarian carcinoma- analysis of 7 phase III trials by AGO Studygroup + ENGOT (2021) (2)
- MRI- and Histologic-Molecular-Based Radio-Genomics Nomogram for Preoperative Assessment of Risk Classes in Endometrial Cancer (2022) (2)
- Is Endometrial Cancer Risk Reduced by Oral Bisphosphonate Use? (2015) (2)
- Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients (2020) (2)
- Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study. (2022) (2)
- DNA methylation signatures to predict the cervicovaginal microbiome status (2020) (2)
- Oxaliplatin (OXA) in patients (pts) with advanced ovarian cancer (AOC) after failure of topotecan (TOPO) based chemotherapy (2002) (2)
- A deep learning solution for detection of homologous recombination deficiency in ovarian cancer using low pass whole-genome sequencing: Evaluation of the analytical performance. (2022) (2)
- Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial. (2016) (2)
- ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit (2003) (2)
- 740P Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): Exploratory biomarker analyses of the phase IIIb OPINION study (2021) (2)
- Erratum: Are monoclonal antibodies a safe treatment for cancer during pregnancy? (Immunotherapy (2013) 5:7 (733-741) DOI: 10.2217/imt.13.64) (2013) (2)
- ORZORA: Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status (2021) (2)
- Different Platinum Schedules in the Treatment of Epithelial Ovarian Cancer (1988) (2)
- Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. (2018) (2)
- The obese endometrial cancer patient : how dowe effectively improve morbidity and mortality in this patient population ? (2016) (2)
- Regioselective γ-Alkylation of tert-Butyl 2,4-Dioxopiperidine-1-carboxylate. (2008) (2)
- Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells (2021) (2)
- Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial (2019) (2)
- Postprogression outcomes in patients with ovarian carcinoma associated with a mutation in a non-BRCA homologous recombination repair gene receiving rucaparib maintenance treatment: Results from the phase III study ARIEL3 (2020) (2)
- OC144: Prospective evaluation of logistic regression models to predict malignancy of adnexal masses prior to surgery (2008) (2)
- Methotrexate with Citrovorum Factor in Low-Risk Gestational Trophoblastic Tumor (1987) (2)
- The WID‐EC test for the detection and risk prediction of endometrial cancer (2022) (2)
- External validation of a nomogram predicting overall survival (OS) of women with uterine leiomyosarcoma (ULMS). (2012) (2)
- Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy. (2020) (2)
- Abstract PR06: ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC) (2018) (2)
- 278 Tamoxifen (TAM) in advanced epithelial ovarian cancer (1983) (2)
- A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML (2018) (2)
- The effect of age on efficacy and safety outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase III, randomized, placebo-controlled maintenance study in patients with recurrent ovarian carcinoma (2019) (2)
- 8050 POSTER Cost-effectiveness of Trabectedin in Combination With Pegylated Liposomal Doxorubicin Hydrochloride for the Treatment of Women With Relapsed Platinum-sensitive Ovarian Cancer in the UK -Analysis Based on the Final Survival Data (2011) (2)
- The European Canadian Intergroup trial (OV10 trial) and the US Gynaecologic Oncology Group trial (GOG 111). (2004) (2)
- 241 Impact of co-medication on survival in patients with ovarian cancer – A analysis of 4 prospective trials of the AGO-OVAR and ENGOT/GCIG collaborators (2021) (1)
- 2022-RA-1028-ESGO Role of radiotherapy in platinum sensitive oligometastatic recurrent ovarian cancer: a valid alternative to delay systemic treatment (2022) (1)
- Ovarian Sex Cord Tumors (2017) (1)
- 2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC) (2015) (1)
- Phase Ib study of RAD001 (R) with pegylated-liposomal doxorubicin (PLD) in patients with advanced solid tumors. (2010) (1)
- Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial. (2023) (1)
- Ovarian Sex Cord-Stromal Tumors (2004) (1)
- Treatment of Minimal Residual Disease (MRD) with Donor Lymphocyte Infusions (DLI) in Acute Leukemia Patients Undergoing an Allogeneic Hemopoietic Stem Cell Transplants (HSCT). (2005) (1)
- Controversies in chemotherapy — what is standard treatment? (2003) (1)
- 8031 POSTER Prediction of Overall Survival (OS) Adjusted by Continuous Platinum-free Interval (PFI) at Fixed Timepoints in Patients With Recurrent Ovarian Cancer (ROC) – Results From OVA-301 (2011) (1)
- Minimal Residual Disease Assessment May Drive Post Remission Therapy in Acute Myeloid Leukemia. It9s Time for MRD-Driven Therapy (2016) (1)
- LB001/#1731 Late-breaking abstract presentation: overall survival by number of prior lines of chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer receiving olaparib treatment or non-platinum chemotherapy in SOLO3 (2022) (1)
- The European society of gynaecological oncology: update on objectives and educational and research activities. (2012) (1)
- Abstract 822: Thienoindoles, a novel class of DNA minor groove alkylating agents highly suited for the generation of novel antibody drug conjugates (ADCs) (2014) (1)
- Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial (2021) (1)
- OC154: Prospective external validation of an ultrasound scoring system to differentiate benign from malignant masses in specific subgroups of adnexal tumors (2008) (1)
- Corrigendum to “Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90)” [Bioorg. Med. Chem. 21 (2013) 7047–7063] (2014) (1)
- The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership (2015) (1)
- Prognostic Value of Minimal Residual Disease Assessed By WT1 Expression Level and Flow Cytometry in Acute Myeloid Leukemia Patients Undergoing Allogeneic Marrow Transplantation (2014) (1)
- Myeloid neoplasms post PARP inhibitors for ovarian cancer (2023) (1)
- Pertuzumab (P) plus chemotherapy (CT) for platinum-resistant ovarian cancer: Safety run-in results of the PENELOPE trial. (2014) (1)
- Reply to M.L. Friedlander et al. (2013) (1)
- 2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine (2022) (1)
- 20th International Meeting of the European Society of Gynaecological Oncology (2017) (1)
- ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma. (2021) (1)
- Tumour-infiltrating lymphocytes (TILs) in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy: A retrospective study (2019) (1)
- O028/#376 Clinical benefit of mirvetuximab soravtansine in ovarian cancer patients with high folate receptor alpha expression: results from the soraya study (2022) (1)
- Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions (2023) (1)
- Prognostic Impact of Minimal Residual Disease Assessment in Elderly Patients with Secondary Acute Myeloid Leukemia. a Comparison between CPX-351 and Intensified Fludarabine-Based Regimens (2021) (1)
- Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Future—Five-Years’ Single-Institution Experience of 762 Consecutive Patients (2022) (1)
- 2022-RA-1295-ESGO The role of intraoperative indocyanine green fluorescence angiography in preventing anastomotic leakage after colorectal resection for advanced ovarian cancer (2022) (1)
- Evaluation of perioperative management of advanced ovarian (tubal/peritoneal) cancer patients: a survey from MITO-MaNGO Groups (2021) (1)
- Genome-wide association study (GWAS) of pazopanib efficacy and safety in patients with ovarian cancer who have not progressed following first-line standard therapy. (2014) (1)
- Randomized phase II trial of NGR-hTNF with an anthracycline in platinum-refractory or -resistant ovarian cancer (OC). (2014) (1)
- 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775 (2022) (1)
- 935PDBRCA1&2 tumoral and germline status for ovarian cancer patients in first line setting within the PAOLA-01 trial (2017) (1)
- Analytical evaluation of a commercial in-house homologous recombination deficiency (HRD) assay for patients with epithelial ovarian cancers and its concordance with a reference standard. (2022) (1)
- 816TiP Randomized phase III trial on niraparib - TSR-042 (dostarlimab) vs physician’s choice CHEmotherapy in recurrent ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) (2021) (1)
- LBA2 Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study (2021) (1)
- Corrigendum to "Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia)" [Eur J Canc. vol. 139 November (2020) Pages 149-168]. (2020) (1)
- A novel oncologist-led BRCA1/2 germline mutation (gBRCAm) testing and counselling model for patients with ovarian cancer: Interim results from the ENGAGE (NCT02406235) study (2016) (1)
- Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation (2020) (1)
- In vitro cytotoxicity of VP-16213 on human ovarian cancer. (1984) (1)
- High Predictive Value of Pre Transplant Minimal Residual Disease Assessment By Combining WT1 Expression and Flow Cytometry in Acute Myeloid Leukemia (2015) (1)
- Robotic modified radical hysterectomy with pelvic lymphadenectomy (2007) (1)
- Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): Results from a subgroup of patient from the MITO-16A-MANGO OV2A phase 4 trial. (2015) (1)
- 880PDPAZOPANIB VERSUS PLACEBO IN WOMEN WITHOUT PROGRESSION AFTER FIRST-LINE CHEMOTHERAPY FOR ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER (AEOC): SECOND INTERIM OVERALL SURVIVAL ANALYSIS FROM THE AGO-OVAR16 TRIAL. (2014) (1)
- Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service. (2020) (1)
- MIRASOL: A randomized, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression (297) (2022) (1)
- Catumaxomab versus catumaxomab plus prednisolone in patients with malignant ascites due to epithelial cancer: results from the CASIMAS study (2012) (1)
- Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS) (2019) (1)
- The wider impact on women's healthMore than cervical cancer? (2006) (1)
- Ovarian cancer. (2006) (1)
- A randomized Phase III trial of durvalumab with chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer (DUO-O): Updated trial endpoint and inclusion of China cohort (329) (2022) (1)
- Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION primary analysis. (1)
- Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line (2018) (1)
- Combining Flow Cytometry and Molecular Assessment Improves the Prognostic Value of Pre-Transplant Minimal Residual Disease in Acute Myeloid Leukemia (2016) (1)
- Correction to: "Safety and dose modification for patients receiving niraparib". (2019) (1)
- Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients with a BRCA mutation: subgroup analysis findings from the SOLO1 trial (2020) (1)
- ICON3 and chemotherapy for ovarian cancer. Authors' reply (2002) (1)
- 3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations (2020) (1)
- Radiation Exposure of Ovarian Cancer Patients: Contribution of CT Examinations Performed on Different MDCT (16 and 64 Slices) Scanners and Image Quality Evaluation (2015) (1)
- Treatment of advanced ovarian cancer (OC): A randomized trial comparing different platinum (P) combinations (1986) (1)
- 1.P.89 Mechanism of hypertriglyceridemia in human apolipoprotein A-IMilano transgenic mice (1997) (1)
- A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia (2015) (1)
- The prognostic value of tumor residuals indicated by surgeon, by radiology or an integrated approach by surgeons' assessment and pre-chemotherapy CT-scan in patients with advanced ovarian cancer: An exploratory analysis of the AGO Study led Intergroup trial AGO-OVAR 12. (2017) (1)
- Trabectedin plus pegylated liposomal doxorubicin (PLD) prior to subsequent platinum chemotherapy in patients with platinum-resistant (PR) recurrent ovarian cancer (ROC): Results from OVA-301 follow-up. (2014) (1)
- Summary of the 18th Biannual Meeting of the European Society of Gynecologic Oncology (ESGO) (2014) (1)
- 19 A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study) (2019) (0)
- 950PGene mutational analyses in 154 ovarian cancer (OC) samples from the ROSiA study of front-line bevacizumab (BEV)-containing therapy for OC (2017) (0)
- Monitoring Ca 125 serum levels (SL) to predict treatment outcome in ovarian cancer patients (OCP) (1985) (0)
- Survival With Cemiplimab in Recurrent Cervical Cancer (2022) (0)
- L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1/SRC/STAT3 signaling (2021) (0)
- CISPLATIN AND PACLITAXEL CONCURRENT TO RADIOTHERAPY IN LOCALLY ADVANCED CERVICAL CANCER: a PHASE II STUDY (2007) (0)
- RECIST/CA-125 progression-free survival and the role of CA-125 surveillance in the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian carcinoma (2021) (0)
- RHABDOMYOSARCOMAS OF THE UTERINE CERVIX: A CASE SERIES FROM TWO LEADING CENTERS. (2018) (0)
- [First-line chemotherapy in advanced ovarian cancer]. (1999) (0)
- Fludarabine, Cytarabine, Daunoxome Plus Dasatinib Has High Efficacy with an Acceptable Toxicity Profile As Either Consolidation or Salvage Regimen in Adult Philadelphia Positive Acute Lymphoblastic Leukemia Patients (2015) (0)
- Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC). (2021) (0)
- Pelvic exenteration in gynecologic oncology: Analysis of short- and long-term surgical outcomes (2020) (0)
- PO-0851: Radiotherapy in patients with cardiac implantable electronic devices:clinical and dosimetric aspects (2018) (0)
- 0005 COMPARISON OF PACLITAXEL, CISPLATIN (TP), VERSUS PACLITAXEL, IFOSFAMIDE, CISPLATIN (TIP), AS NEOADJU-VANT CHEMOTHERAPY TO RADICAL SURGERY IN LOCALLY ADVANCED SQUAMOUS CELL CERVICAL CARCINOMA (LASCCC): THE SNAP-02 ITALIAN STUDY (2005) (0)
- Allogeneic Transplanst for ACUTE Myeloid Leukemia: Cut Off Levels of WT1 Expression in 207 Patients and Pre-Emptive Therapy of Relapse (2015) (0)
- 2022-RA-1289-ESGO Understanding clinical and pathological heterogeneity of endometrial cancer with no specific molecular profile (NSMP) (2022) (0)
- 991TiPFORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer (2017) (0)
- ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC). (2021) (0)
- 560 Analysis of 168 primary adult ovarian granulosa cell tumors, its clinicopathological outcome, and risk factors for recurrence (2021) (0)
- ICION3 and chemotheraphy for avarian camcer (2002) (0)
- [Early diagnosis and prevention of female genital neoplasms in a clinic: preliminary evaluations]. (1982) (0)
- Minimal Residual Disease After the First Cycle of Chemotherapy in Acute Myeloid Leukemia: A Comparative Study of WT1 RQ-PCR and 4-Color Flow Cytometry. (2012) (0)
- Impact of the trifunctional antibody catumaxomab followed by systemic chemotherapy (CTX) on overall survival (OS): Results of a subgroup analysis in patients (pts) with relapsed ovarian cancer (OC) and malignant ascites (MA). (2013) (0)
- Finding the Best Therapy for Elderly Frail AML Patients: A Retrospective Comparison of 5-Azacytidine and Intensive Approach (2016) (0)
- Combined overexpression of WT1 and BAALC genes May Predict AML evolution in MDS Patients (2013) (0)
- 16/#430 Phase 2 results of relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer with and without prior bevacizumab (2022) (0)
- Phase II study of esorubicin (4 ′ deoxydoxorubicin) in anthracycline naive patients with ovarian cancer (1990) (0)
- Oxaliplatin in patients with advanced ovarian cancer after failure of Topotecan and/or liposomal doxorubicin based chemotherapy (2003) (0)
- ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC). (2022) (0)
- A nomogram to predict progression-free survival benefit with maintenance olaparib and bevacizumab following response to first line chemotherapy in advanced ovarian cancer (305) (2022) (0)
- The European Society of Gynaecological Oncology: Update on Objectives and Educational and Research Activities (2012) (0)
- Impact of upper abdominal surgery on residual tumour and survival in patients with advanced ovarian and fallopian tube cancer. A large single institution experience (2010) (0)
- 80 Phase I–II study of cisplatin (DDP) and paclitaxel (PTX) concomitant to external beam radiotherapy (EBRT) and pulsed-dose-rate brachytherapy (PDRBT) in cervix cancer (2001) (0)
- Abstract A149: NMS-P945, a highly active payload for antibody drug conjugates generation (2015) (0)
- Role of Pelvic Exenteration in the Treatment of Persistent or Recurrent Gynecological Cancers (2020) (0)
- Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor (2014) (0)
- O14-1 Pembrolizumab + chemotherapy in Japanese patients with persistent, recurrent, or metastatic cervical cancer: KEYNOTE-826 (2022) (0)
- Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence (2023) (0)
- Effect of progression-free interval (PFI) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: an analysis from the phase 3 study ARIEL3 (2019) (0)
- Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775. (2023) (0)
- A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma (2018) (0)
- OC152: Prevalence of cancer and optimal cut‐off levels for mathematical models to distinguish between benign and malignant adnexal masses (2008) (0)
- ICON2 trial (1999) (0)
- The developmental origins of high grade serous ovarian cancer. (2019) (0)
- OC27.03: Conservative management and ultrasonographic longitudinal follow‐up of borderline ovarian tumors recurrences after fertility sparing surgery (2010) (0)
- Maintenance Therapy for First-Line Treatment of Ovarian Cancer: Is This the Strategy for the Future? (2014) (0)
- Advanced-stage ovarian cancer metastases to sigmoid colon mesenteric lymph nodes: Clinical consideration of tumor spread and biologic behavior (2011) (0)
- 884TiP AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer (2020) (0)
- Prognostic effects of clinical and tumor (t) factors in bevacizumab (BEV)-treated patients (pts) with ovarian cancer (OC). (2016) (0)
- Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775. (2022) (0)
- COMPARISON BETWEEN LAPAROSCOPY AND LAPAROTOMY IN THE SURGICAL RE- STAGING OF GRANULOSA CELL TUMORS OF THE OVARY (2018) (0)
- Treatment patterns and BRCA testing practices in platinum-sensitive recurrent serous ovarian cancer: a Spanish medical record review (2016) (0)
- Maintenance of quality of life (QoL) and general health state in patients with malignant ascites during treatment with the trifunctional antibody catumaxomab: results from the phase III b CASIMAS trial (2012) (0)
- 943TiPTRABECTEDIN AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) VERSUS CARBOPLATIN AND PLD IN PARTIALLY PLATINUM-SENSITIVE OVARIAN CANCER PATIENTS: INOVATYON STUDY. (2014) (0)
- Abstract A66: The CD73+/CD24- subpopulation of ovarian cancer cells is enriched in cancer stem cells. (2016) (0)
- Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial. (2021) (0)
- Abstract GMM-018: CD73: A NEW DRIVER AND A THERAPEUTIC TARGET IN OVARIAN CANCER STEM CELLS (2019) (0)
- Maintenance olaparib monotherapy for platinum-sensitive relapsed ovarian cancer in patients without a germline BRCA1/BRCA2 mutation: Secondary safety results from the phase IIIb OPINION study (128) (2022) (0)
- Tisotumab vedotin versus investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG 3057, trial in progress). (2021) (0)
- Combined Assessment of WT1 and BAALC Expression Levels Improves Risk Stratification in Myelodysplastic Syndromes (2014) (0)
- TP023/#1560 A phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept in combination with weekly paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66) (2022) (0)
- BRCA tumor test in ovarian cancers: The changing role of molecular pathology in the era of PARP inhibitor (PARPi) therapy. (2019) (0)
- TP034/#1534 Randomized phase III trial on niraparib-TSR-042 (Dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, primary peritoneal cancer platinum resistant patients: nitche trial(MITO 33) (2022) (0)
- Chemotherapy for sex-cord stromal tumors (2004) (0)
- Feasibility of intraoperative radiotherapy with electrons in breast cancer patients with cardiac devices (2016) (0)
- Quality of life in patients with malignant ascites during catumaxomab treatment: Results from the CASIMAS trial. (2012) (0)
- D02Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): results from a subgroup of patient from the MITO-16A-MANGO OV2A phase 4 trial (2015) (0)
- ICON2 trial (multiple letter) [1] (1999) (0)
- Author Correction: Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock (2022) (0)
- O018/#482 Updated safety of lenvatinib + pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775 (2022) (0)
- Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial. (2023) (0)
- ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer. (2022) (0)
- Fludarabine, cytarabine and Idarubicin (FLAI-5) with or without Gemtuzumab Ozogamicin Is an Effective and Well Tolerated Regimen for Younger AML Patients: Real Life Data from a Single Center Register (2014) (0)
- Aggressive surgical debulking at time of primary and interval surgery at referral oncologic center: Surgical and oncological outcomes (2014) (0)
- Abstract 1414: Molecular and functional characterization of ovarian cancer stem cells (2015) (0)
- High Prognostic Value of a 3-Genes Molecular Score in Non-High Risk Acute Promyelocytic Leukemia Treated with AIDA 2000 Protocol: A Retrospective Study from a Regional Register (2015) (0)
- 164 ENGOT-cx11/GOG 3047/KEYNOTE-A18: a phase 3, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer (2020) (0)
- TP016/#1442 Keynote-C93/GOG-3064/ENGOT-EN15: phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma (2022) (0)
- Abstract 3434: Selective glucocorticoid receptor modulation reveals a new role for CLEC10A in patients with solid tumors (2023) (0)
- Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma (2022) (0)
- SECOND-LINE TREATMENT OF PARTIALLY-PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER: A MANGO - PIEMONTE E VALLE D'AOSTA CANCER NETWORK ITALIAN MULTICENTRIC RETROSPECTIVE STUDY (2010) (0)
- EPV084/#549 Role of dose-dense neoadjuvant chemotherapy with paclitaxel and carboplatin in locally advanced cervical cancer (2021) (0)
- PB1730 A SIMPLE FLOW CYTOMETRY-BASED SCORE MAY OPTIMIZE TESTING FOR BIALLELIC CEBPA MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA PATIENTS (2019) (0)
- VP66.28: Conservative management and ultrasonographic longitudinal follow‐up of borderline ovarian tumour recurrences in pregnant women (2020) (0)
- Intraoperative radiotherapy with electrons (ELIOT) as partial breast irradiation for patients with Cardiac Implantable Electronic Device (CIED) (2020) (0)
- Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice. (2023) (0)
- Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial. (2022) (0)
- Structure of CDK2-CYCLIN A with a Pyrazolo(4,3-h) quinazoline-3- carboxamide inhibitor (2010) (0)
- OC147: Confirming the limited role of CA‐125 for adnexal mass diagnosis (2008) (0)
- Detection of an Unbalanced Ratio Between WT1 Isoforms in Acute Myeloid Leukemia and Its Correlation with Molecular Abnormalities. (2012) (0)
- INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line (2023) (0)
- EFFECT OF PRIOR BEVACIZUMAB THERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN CARCINOMA (ROC) IN THE PHASE 3 STUDY ARIEL3 (2018) (0)
- Proffered Paper Session (Tuesday, 29 September)Gynaecological CancerOral2704 Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: Results of an international multicenter study comprising 545 patients (2015) (0)
- Options for primary chemotherapy in advanced ovarian cancer: the European perspective. (1994) (0)
- Cyclophosphamide (C), adriamycin (A) and cisplatin (P) as second line chemotherapy (CH) of epithelial ovarian cancer (EOC): Mature results in 118 patients (Pts) (1989) (0)
- Implementing clinical practice guidelines: time to assess it (2020) (0)
- Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden (2019) (0)
- SIRT6 Inhibition As a Novel Approach for Treating Acute Myeloid Leukemia (2016) (0)
- C26 A rabbit model of atherosclerosis which mimics human soft, lipid-rich, plaques (1999) (0)
- 2022-RA-1638-ESGO Randomized phase III trial on Niraparib-TSR-042 (dostarlimab) versus physician’s choice in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) (2022) (0)
- P-140 Combined overexpression of WT1 and BAALC may predict evolution in MDS (2013) (0)
- 58 KEYNOTE-826: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer (2021) (0)
- In memoriam: Charles Paul Morrow (2022) (0)
- Matrix Gla Protein acts as a driver of stemness and tumor initiation in ovarian cancer (2022) (0)
- High WT1 Expression Has An Independent Positive Influence On CR Rate and EFS in Non M3 AML Patients Treated with Chemotherapy. (2009) (0)
- EP-1596: Intraoperative radiotherapy with electrons in breast cancer patients with cardiac devices (2016) (0)
- Author Correction: Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock (2022) (0)
- Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159]. (2021) (0)
- EP850 Incidence and survival impact of abdominal wall metastases in advanced low-grade serous epithelial ovarian cancer: a single center experience (2019) (0)
- 88 Cervical re-injection to improve sentinel lymph node detection in endometrial cancer (2019) (0)
- B-Raf Kinase V600E mutant in complex with a diarylthiazole B-Raf Inhibitor (2014) (0)
- ICON2 TRIAL. AUTHORS' REPLY (1999) (0)
- Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers (2022) (0)
- 296 INVITED Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer (2011) (0)
- Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (2022) (0)
- Corrigendum to 'Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary' [Gynecologic Oncology 157 (2020) 85-88]. (2021) (0)
- 48INTARGETED THERAPY OF OVARIAN CANCER: BEYOND ANGIOGENESIS. (2014) (0)
- PROGNOSTIC VALUE OF SERUM CA125 AND MARKER HALF-LIFE (T½) FOR LONG-TERM PROGRESSION FREE AND OVERALL SURVIVAL AND OPTIMAL INTERVAL DEBULKING SURGERY (IDS) IN ADVANCED OVARIAN CARCINOMA. A EORTC-GCG STUDY (2004) (0)
- 2022-RA-913-ESGO Clinical performance evaluation of a novel deep learning solution for homologous recombination deficiency detection (2022) (0)
- 0178: Oral Gimatecan in Women with Progressing or Recurring Advanced Epithelial Ovarian, Fallopian Tube and Peritoneal Cancers (2006) (0)
- Secondary de-bulking surgery in recurrent ovarian cancer (2017) (0)
- Stereotactic Body Radiotherapy For Oligometastatic Ovarian Cancer: A Step Towards A Drug Holiday (2018) (0)
- 1.P.78 Role of human apolipoproteins in cell cholesterol efflux: Studies with transgenic mice (1997) (0)
- Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age (2019) (0)
- Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial. (2023) (0)
- Lipid metabolism in mice expressing human apolipoprotein A-IMilano (1997) (0)
- 2022-RA-657-ESGO ENGOT-ov65/KEYNOTE-B96: phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer (2022) (0)
- DNA methylation signatures to predict the cervicovaginal microbiome status (2020) (0)
- Relationship between Clinical/Hematological Response and Increase of Plamacells in the Bone Marrow of Patients with Chronic Myelogenous Leukemia Imatinib Mesylate Treatment (631). (2007) (0)
- Letter to the Editor (2004) (0)
- Ovarian Surface Epithelium The Differential Role of L 1 in Ovarian Carcinoma and Normal (2008) (0)
- Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (023) (2022) (0)
- Robotic Surgery: New Way to Change the Surgical Approach for Endometrial Cancer in a Cancer Center (2008) (0)
- ENGAGE: Evaluation of a streamlined oncologist-led BRCA mutation (BRCAm) testing and counselling model for patients with ovarian cancer. (2017) (0)
- Encouraging results of relacorilant in ovarian cancer (2022) (0)
- 2022-RA-659-ESGO The role of molecular classification in endometrial cancers with lymph nodes metastasis (2022) (0)
- Third international symposium on the role of MPA in endocrine-related tumours564 Second and third-line chemotherapy in advanced and recurrent endometrial cancer (1983) (0)
- OC27.03: Conservative management and ultrasonographic longitudinal follow-up of borderline ovarian tumors recurrences after fertility sparing surgery (2010) (0)
- 2022-RA-909-ESGO AGO-OVAR 28/ENGOT-ov57: niraparib vs niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer (a multicentre randomised phase III trial) (2022) (0)
- Evidence for Increased Bone Marrow Lymphoplasmocytoid Cells and SDF1 Secretion in imatinib Treated CML. Relationship with Clinical/hemathological Response (2008) (0)
- Trabectedin in ovarian cancer (2010) (0)
- Bevacizumab combined with first-line carboplatin and paclitaxel for metastatic/recurrent/persistent cervical cancer: primary results from the global single-arm phase II CECILIA study (2019) (0)
- Effect ofastreptococcal preparation (OK432) onnatural killer activity oftumour-associated lymphoid cells inhuman ovarian carcinoma andonlysis offresh ovarian tumourcells (1983) (0)
- 2022-RA-376-ESGO Clinicopathological characteristics of ‘multiple-classifiers’ in endometrial cancer (2022) (0)
- EP814 TGFβ pathway activation is a predictor of progression free and overall survival in advanced high-grade serous ovarian cancer according to the surgical aggressiveness and rate of cytoreduction of different oncologic centers (2019) (0)
- structure of HSP90 with an inhibitor bound (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Nicoletta Colombo?
Nicoletta Colombo is affiliated with the following schools:
